ICOS and PD-1 — Drug Target

All drugs that target ICOS and PD-1 — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

ICOS agonist + PD-1 inhibitor combination · Checkpoint inhibitor combination (ICOS agonist + PD-1 inhibitor)

Phase 3 pipeline (2)

• IPI3/NIVO1 · Vastra Gotaland Region · ICOS agonist + PD-1 inhibitor combination · Oncology
  IPI3/NIVO1 is a combination of an inducible T-cell co-stimulator (ICOS) agonist and a PD-1 inhibitor that enhances anti-tumor immune responses by activating T cells while removing inhibitory checkpoint signals.
• IPI1/NIVO3 · Vastra Gotaland Region · Checkpoint inhibitor combination (ICOS agonist + PD-1 inhibitor) · Oncology
  IPI1/NIVO3 is a combination of an inducible T-cell co-stimulator (ICOS) agonist and a PD-1 inhibitor that enhances anti-tumor immune responses by activating T cells while removing inhibitory checkpoint signals.